Long-term Safety Study of Rimegepant for Migraine in Children and Adolescents
This study is looking at the long-term safety of rimegepant (PF-07899801), a medication for the acute treatment of migraine, in children and adolescents aged 6 to 17 years old. Researchers want to understand how often and how severely side effects occur, including serious side effects and those that lead to stopping the medication. They will also look for any significant changes in lab test results. You may be able to join if you have a history of migraine for at least 6 months, experience 1 to 8 moderate or severe migraine attacks per month, and need treatment for migraines. The study plans to enroll 600 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 600 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse events and lab abnormalities for 58 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
At a glance
Conditions
Where it's being run
124 sites across 36 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The frequency and severity of on-treatment and treatment-emergent adverse events, serious adverse events, adverse events leading to discontinuation, clinically significant lab abnormalities58 weeks
To evaluate the safety and tolerability of rimegepant in children and adolescents (6 to \< 18 years of age).